Surrozen, Inc. (NASDAQ:SRZN – Free Report) – HC Wainwright dropped their Q3 2026 earnings per share estimates for shares of Surrozen in a note issued to investors on Monday, August 10th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($1.33) per share for the quarter, down from their prior estimate of ($1.19). HC Wainwright has a “Buy” rating and a $44.00 price target on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($7.20) per share. HC Wainwright also issued estimates for Surrozen’s Q4 2026 earnings at ($1.31) EPS, FY2027 earnings at ($5.01) EPS, FY2028 earnings at ($5.28) EPS, FY2029 earnings at ($5.47) EPS and FY2030 earnings at ($5.53) EPS.
Several other equities analysts have also recently weighed in on SRZN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research report on Friday, July 17th. TD Cowen started coverage on Surrozen in a report on Tuesday, April 21st. They set a “buy” rating on the stock. Finally, Zacks Research raised Surrozen from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.00.
Surrozen Price Performance
NASDAQ:SRZN opened at $25.05 on Wednesday. The company has a market cap of $290.83 million, a P/E ratio of -0.62 and a beta of 0.52. The stock’s fifty day moving average price is $22.91 and its two-hundred day moving average price is $25.50. Surrozen has a 1 year low of $9.66 and a 1 year high of $35.00.
Surrozen (NASDAQ:SRZN – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.88. The business had revenue of $5.00 million during the quarter, compared to analysts’ expectations of $0.47 million.
Insider Buying and Selling
In related news, major shareholder Tcg Crossover Gp Ii, Llc sold 325,000 shares of the stock in a transaction on Wednesday, July 22nd. The stock was sold at an average price of $21.25, for a total value of $6,906,250.00. Following the transaction, the insider owned 574,047 shares of the company’s stock, valued at $12,198,498.75. This represents a 36.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 31.74% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Surrozen
Hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC lifted its position in Surrozen by 557.1% in the 4th quarter. Millennium Management LLC now owns 721,266 shares of the company’s stock worth $16,301,000 after buying an additional 611,497 shares during the last quarter. Spruce Street Capital LP bought a new position in Surrozen during the fourth quarter valued at approximately $9,764,000. Kalehua Capital Management LLC bought a new position in Surrozen during the fourth quarter valued at approximately $8,705,000. Braidwell LP raised its stake in shares of Surrozen by 235.7% during the fourth quarter. Braidwell LP now owns 470,000 shares of the company’s stock worth $10,622,000 after acquiring an additional 330,000 shares in the last quarter. Finally, Perceptive Advisors LLC purchased a new position in shares of Surrozen during the first quarter worth approximately $6,682,000. 66.57% of the stock is currently owned by hedge funds and other institutional investors.
Surrozen Company Profile
Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.
The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.
Featured Stories
- Five stocks we like better than Surrozen
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
